Cenegermin: Emerging Therapeutic Tools In The Field Of Ophthalmic Regenerative Medicine
Cenegermin is sold under the trade name Oxervate, also known as recombinant human nerve growth factor, and is a recombinant form of human nerve growth factor.
It is a peripheral selective agonist of tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).
What Is Neurotrophic Keratopathy (NK)?
Neurotrophic keratosis is a corneal lesion caused by damage or degeneration of the corneal nerves, typically manifested as corneal epithelial defects, dry eye syndrome, corneal edema, and other symptoms.
The occurrence of this disease is often related to factors such as trauma, surgical sequelae, viral infections, etc. In severe cases, it may lead to corneal perforation and vision loss.
Due to the lack of effective treatment methods, many patients need to rely on artificial tears and other adjuvant therapies for a long time, which greatly affects their quality of life.
Cenegermin: Innovative Therapeutic Drugs
Cenegermin(Oxervate ®). It is a recombinant human neurotrophic factor (NGF) ophthalmic drug specifically used for the treatment of neurotrophic corneal disease.
As the first approved NGF therapy, Cenegermin promotes the repair and regeneration of corneal epithelial cells, helps restore the natural barrier function of the cornea, and improves the self repair ability of the eye, significantly reducing corneal lesions and dry eye symptoms.
It provides unprecedented treatment options for patients by directly stimulating the repair of corneal nerve endings, restoring neurotrophic function, and improving tear secretion in the eye and the natural repair ability of the cornea.
Cenegermin: Significant Therapeutic Effect And Improvement In Quality Of Life
Oxervate Cenegermin has demonstrated significant therapeutic efficacy in multiple clinical studies.
Research has shown that it can significantly improve corneal epithelial defects, reduce eye discomfort in patients, and enhance the self repair ability of the cornea.
Research data also shows that it can help restore tear secretion, effectively alleviate dry eye symptoms, and significantly improve patients’ vision and quality of life.
The most encouraging thing is that it provides new hope for patients who are ineffective or resistant to traditional treatments.
Many patients experience significant improvement in symptoms, visual recovery, and good tolerance during treatment.
Cenegermin: Convenient Treatment Plan
Oxervate Cenegermin is treated with eye drops, usually recommended 6 times a day, until significant improvement in corneal epithelial defects.
Based on the patient’s treatment response and clinical needs, doctors may adjust the dosage according to specific circumstances.
Compared with traditional treatment methods, Oxervate’s eye drops are more convenient to use and can be completed in a home environment, eliminating the need for frequent medical visits and improving treatment compliance.
Cenegermin: Side Effects And Safety
Cenegermin treatment is usually well tolerated. The most common side effects are eye discomfort, such as burning sensation, dry eyes, and foreign body sensation in the eyes.
These symptoms usually appear in the early stages of treatment and gradually alleviate during the treatment process.
Overall, the side effects of Cenegermin are relatively mild, and most of them are temporary.
During the treatment process, patients should undergo regular eye examinations to ensure the safety of medication use and adjust the treatment plan according to the doctor’s advice.
Cenegermin: Bringing New Hope To Patients
The approval of Cenegermin not only provides innovative treatment options for patients with neurotrophic keratosis, but also offers new directions for precision and personalized treatment in the field of ophthalmology.
As the first approved NGF therapy, Cenegermin provides important clinical evidence for the treatment of corneal lesions, relief of dry eye symptoms, and restoration of vision, and is expected to play an important role in more ophthalmic diseases in the future.
Summary
The approval of Cenegermin for marketing has brought unprecedented treatment opportunities for patients with neurotrophic keratosis.
As an innovative neurotrophic factor ophthalmic drug, Cenegermin not only effectively promotes corneal repair and alleviates dry eye symptoms, but also significantly improves the quality of life of patients.
In the future, with the global promotion of it, more patients will benefit from it.
However, DengYue‘s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to contact us to buy Oxervate Cenegermin.
Information from HK DengYueMedicine, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
